Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists

Journal of Neurosurgery

Volumn 84, Issue 3, 1996, Pages 503-507

  Zuccarello, Mario ^a   Soattin, Giovanni B ^b   Lewis, Adam I ^b   Breu, Volker ^b   Hallak, Hussein ^b   Rapoport, Robert M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

cerebral vasospasm; endothelin receptor antagonist; rabbit basilar artery; subarachnoid hemorrhage

Indexed keywords

3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; BOSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BASILAR ARTERY; BRAIN ISCHEMIA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; SUBARACHNOID HEMORRHAGE; VASOSPASM;

EID: 0030062784     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.84.3.0503     Document Type: Article

References (39)

1. B receptors. FEBS Lett 334:210-214, 1993
2. Clozel M, Breu V, Burri K, et al: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365:759-761, 1993
3. Clozel M, Breu V, Gray GA, et al: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228-235, 1994
4. B receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873, 1992
5. A receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52:825-834, 1993
6. A-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol 22 (Suppl 8): S332-S335, 1993
7. A) receptor-selective antagonists. J Med Chem 38:1259-1263, 1995
8. Feger GI, Schilling L, Ehrenreich H, et al: Endothelin-induced contraction and relaxation of rat isolated basilar artery: effect of BQ-123. J Cereb Blood Flow Metab 14:845-852, 1994
9. Filep JG, Clozel M, Fournier A, et al: Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat. Br J Pharmacol 113:845-852, 1994
10. Foley PL, Caner HH, Kassell NF, et al: Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 34:108-113, 1994
11. Fujimori A, Yanagisawa M, Saito A, et al: Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage. Lancet 336:633, 1990 (Letter)
12. Hamann G, Isenberg E, Strittmatter M, et al: Absence of elevation of big endothelin in subarachnoid hemorrhage. Stroke 24:383-386, 1993
13. Hirose H, Ide K, Sasaki T, et al: The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 277:77-87, 1995
14. A receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg 81:759-764, 1994
15. A receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 195:969-975, 1993
16. Kitazono T, Heistad DD, Faraci FM: Dilatation of the basilar artery in response to selective activation of endothelin B receptors in vivo. J Pharmacol Exp Ther 273:1-6, 1995
17. Kitazono T, Heistad DD, Faraci FM: Enhanced responses of the basilar artery to activation of endothelin-B receptors in stroke-prone spontaneously hypertensive rats. Hypertension 25: 490-494, 1995
18. Masaoka M, Suzuki R, Hirata Y, et al: Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1:1402, 1989 (Letter)
19. Matsumura Y, Ikegawa R, Suzuki Y, et al: Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci 49:841-848, 1991
20. A receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci 52:1869-1874, 1993
21. Ohlstein EH, Beck GR Jr, Douglas SA, et al: Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 271:762-768, 1994
22. Pickard JD, Murray GD, Illingworth R, et al: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. Br Med J 298:636-642, 1989
23. Plane F, Garland CJ: Differential effects of acetylcholine, nitric oxide and levcromakalim on smooth muscle membrane potential and tone in the rabbit basilar artery. Br J Pharmacol 110: 651-656, 1993
24. Rand VE, Garland CJ: Endothelium-dependent relaxation to acetylcholine in the rabbit basilar artery: importance of membrane hyperpolarization. Br J Pharmacol 106:143-150, 1992
25. Roux S, Löffler BM, Gray GA, et al: The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37:78-85, 1995
26. Sasaki T, Kassell NF, Yamashita M, et al: Barrier disruption in the major cerebral arteries following experimental subarachnoid hemorrhage. J Neurosurg 63:433-440, 1985
27. B-type endothelin receptor. J Cereb Blood Flow Metab 5:699-705, 1995
28. Seifert V, Löffler BM, Zimmermann M, et al: Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 82:55-62, 1995
29. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89:1203-1208, 1994
30. Shigeno T, Clozel M, Sakai S, et al: The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37:87-91, 1995
31. Shigeno T, Mimi T, Yanagisawa M, et al: Possible role of endothelin in the pathogenesis of cerebral vasospasm. J Cardiovasc Pharmacol 17 (Suppl 7):S480-S483, 1991
32. Suzuki H, Sato S, Suzuki Y, et al: Increased endothelin concentration in CSF from patients with subarachnoid hemorrhage. Acta Neurol Scand 81:553-554, 1990
33. Suzuki R, Masaoka H, Hirata Y, et al: The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 77:96-100, 1992
34. Takase H, Moreau P, Lüscher TF: Endothelin receptor subtypes in small arteries: studies with FR139317 and bosentan. Hypertension 25:739-743, 1995
35. Willette RN, Zhang H, Mitchell MP, et al: Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 25:2450-2456, 1994
36. Yamaura I, Tani E, Maeda Y, et al: Endothelin-1 of canine basilar artery in vasospasm. J Neurosurg 76:99-105, 1992
37. Zuccarello M, Kassell NF, Sasaki T, et al: Barrier disruption in the major cerebral arteries after experimental subarachnoid hemorrhage in spontaneously hypertensive and normotensive rats. Neurosurgery 21:515-522, 1987
38. B receptors in subarachnoid hemorrhage-induced cerebral vasospasm. Eur J Pharmacol 259:R1-2, 1994
39. Zuccarello M, Romano A, Passalaqua M, et al: Decreased endothelium-dependent relaxation in subarachnoid hemorrhage-induced vasospasm: role of ET-1. Am J Physiol 269: H1009-H1015, 1995